Innovations
Commented by Nico Popp on March 30th, 2026 | 08:30 CEST
A Paradigm Shift in Oncology: Core Stocks Roche & Galderma and the High-Leverage Opportunity in Vidac Pharma
Medical advances affect us all. Oncology is also undergoing a transformation. As conventional immunotherapies for skin cancer increasingly reach their limits, clinical research is shifting its focus to correcting defective tumor metabolism. The Warburg effect, where cancer cells shift energy production to aerobic glycolysis to fuel uncontrolled growth, offers a promising entry point. This dynamic development landscape is exacerbated by an impending patent cliff, which, according to calculations by the consulting firm PwC, threatens industry revenues of USD 104 billion by 2028, as many patents for active ingredients are expiring. Currently, market researchers at Fortune Business Insights estimate the volume of the global oncology market for 2026 at USD 286.36 billion. While pharmaceutical giant Roche secures its market leadership and the Galderma Group dominates standard dermatological care, biotechnology company Vidac Pharma is targeting the metabolic vulnerability of cancer cells with a completely novel mechanism of action, aiming to effectively shut down the cancer.
Read
Commented by Mario Hose on February 27th, 2026 | 07:05 CET
Revolution in cancer therapy: Vidac Pharma attacks the cancer throne of the big players! Why the smaller competitor could steal the show from giants like Bayer and BioNTech!
The world of biotechnology and pharmaceuticals is currently in turmoil, as technological breakthroughs and strategic realignments promise an exciting future for investors. The focus is particularly on Vidac Pharma, an innovative company that wants to revolutionize the fight against cancer with a completely new approach to oncology and is currently celebrating one milestone after another. While Vidac Pharma shines with impressive clinical progress and strong internal backing from its main shareholder, Dr. Max Herzberg, industry giant Bayer has recently struggled with the late effects of the Monsanto acquisition, but is now increasingly being touted as an exciting candidate for a split or takeover by financial investors. At the same time, BioNTech remains synonymous with cutting-edge mRNA technology, with the market eagerly awaiting the next phase after the pandemic. In this dynamic environment, Vidac Pharma is emerging as a particularly bright star in the biopharmaceutical sky, causing a sensation with its unique method of specifically normalizing the metabolism of cancer cells.
Read
Commented by André Will-Laudien on February 4th, 2026 | 07:10 CET
Starting signal! Biotech sector benefits from rotation! Keep an eye on Evotec, Bayer, Vidac Pharma, and BioNTech
The stock market has started 2026 on a positive note. The mining and commodities sector recently proved that return opportunities are not limited to the technology sector, with several stocks doubling in price and a few even increasing tenfold. A breath of fresh air is needed, because other sectors also want to enjoy the stock market spring. Life science stocks have indeed taken a break for almost three years. But now they are back! After a long period of silence, selected companies are showing the first signs of a technical recovery. For investors with a penchant for opportunities and timing, now is the time to rethink old strategies and realign portfolios. In cancer research, recent breakthroughs in personalized immunotherapies have significantly increased the prospects of success for clinical trials. We take a closer look.
Read
Commented by André Will-Laudien on January 2nd, 2026 | 07:05 CET
Attention - fasten your seatbelts! 2026 could be a rocket launch for Novo Nordisk, Evotec, Bayer, and Vidac Pharma
The stock market is starting the new year 2026 in a buoyant mood. The mining and commodities sector showed that it is not only possible to make money with tech stocks, with almost every stock doubling in value, and some even increasing tenfold. The coming year, however, could bring yet another shift in perspective. The biotech sector has been quiet for quite some time, but some of the protagonists in our selection are showing, in part, significant technical base formations. For risk-aware investors, it may be time to reshuffle more decisively and realign portfolios. Come in and find out!
Read
Commented by Nico Popp on December 9th, 2025 | 07:05 CET
Attacking the fuel that feeds tumors: Why Roche, Pfizer, and Vidac Pharma are redefining oncology
Modern cancer therapy is no longer about blunt-force attacks, but rather precise, targeted interventions. While oncology in recent decades has been dominated by non-specific cell toxins, today's research resembles surgical intervention in the biological software of a disease. Industry heavyweights, Roche and Pfizer, are securing their market positions with gigantic portfolios of immunotherapies. But away from the corporate headquarters of Basel and New York, agile biotech pioneers are working on approaches that attack the very foundation of cancer cells: their energy supply. Those who pull the plug on cancer cells could be among the big winners in the biotech sector in 2026.
Read
Commented by André Will-Laudien on November 27th, 2025 | 07:55 CET
Black Friday: DAX explodes, and biotech is back in vogue: Watch out for 100% gains at Bayer, Vidac Pharma, and Novo Nordisk
The stock market has managed to break out of its consolidation phase, and the upward trend is continuing toward the end of the year. There are signs of hope for the Leverkusen-based pharmaceutical company Bayer, and Vidac Pharma is moving into the primary segment of the Düsseldorf over-the-counter market. The well-known Novo Nordisk, whose share price has been destroyed, is experiencing its fourth sell-off in three months. Some analysts are now turning positive. Investors should now be aware that prices in the biotech sector have fallen so low that even minor news items are enough to cause prices to skyrocket. Especially during the year-end portfolio adjustments, prices often reach absurd levels. We help you navigate the thicket of valuations.
Read
Commented by André Will-Laudien on November 25th, 2025 | 07:50 CET
AI mania, critical metals, and gold! Keep an eye on blockbuster stocks such as BASF, RZOLV Technologies, and Barrick Mining
The breathtaking advances in high-tech and artificial intelligence require a strong focus on raw materials companies in order to provide the necessary strategic metals in a timely manner. Securing supply chains is all the more important for Western industries because the availability of raw materials is subject to geopolitical skirmishes between some countries that still control the decisive masses in critical areas. This is particularly true for China and Russia. If nothing arrives in the West, production lines come to a standstill or company managers have to accept expensive detours. For equity investors, it is always worthwhile to take a clear look at the key levers. However, the focus is also on the manufacturing processes.
Read
Commented by André Will-Laudien on November 24th, 2025 | 09:25 CET
DAX up, NASDAQ down! Automotive sector back in focus with Mercedes-Benz, WashTec, BYD, and VW
The correction in the growth markets continues. Even crypto investors, who are used to success, are now complaining about the pronounced market weakness. November and December are usually good months for the stock market. However, because September and October performed so exorbitantly well, profits are now apparently being taken across the board. For German blue chips, the whole thing has been mild so far, and according to general valuation rules, they also have more room for upward movement. We are diving into the world of electric vehicles and combustion engines, where P/E ratios between 4 and 12 are the norm and real, tangible goods are traded. It is time to put away the AI toys and start the machines.
Read
Commented by Armin Schulz on November 18th, 2025 | 07:05 CET
Patents, potential, takeover candidate? Making money with less risk: The secret of BioNxt Solutions
In the high-risk world of biotechnology, the path from the laboratory to an approved drug is often an ordeal. Canadian company BioNxt Solutions may have found the key to a less painful path. Instead of developing expensive and uncertain new active ingredients, the Company refines proven drugs with innovative administration technology. The past few months have brought a remarkable series of successes that not only confirm the technology but also significantly increase the strategic value of the Company. For investors, this could be a rare opportunity.
Read
Commented by Fabian Lorenz on November 17th, 2025 | 07:10 CET
Out of BioNTech? Into Evotec and Vidac shares? What is going on with Johnson & Johnson?
Big news in biotech: Pfizer is selling its entire stake in German biotech champion BioNTech. Should investors consider doing the same? Meanwhile, Vidac Pharma is providing more and more reasons for a price explosion. The Company is developing a novel cancer therapy and has received approval to begin phase 2 clinical trials in Germany. It is also reportedly in talks with Johnson & Johnson. Might the pharmaceutical giant even make a move? Evotec, on the other hand, has recently sent mixed signals. Another milestone payment is ringing the cash register, and insider transactions are drawing attention. Yet the stock is trading at a multi-year low.
Read